Biotest AG policy statement on the German Supply Chain Due Diligence Act (LkSG)

Status: 01.01.2024

1. The Biotest Group

Biotest is a global supplier of biological medicinal products derived from human plasma. Biotest's products are primarily used in the fields of clinical immunology, haematology and intensive care medicine. They make it possible to treat people with severe, often chronic diseases in a targeted manner and significantly improve their quality of life.

Within our specialist areas, we are active from preclinical and clinical development to production and global marketing. At our main site in Germany, we develop and produce preparations from human plasma, which we either collect in our own donation centers or purchase from qualified and audited suppliers. In addition, we are represented worldwide by our own sales companies and cooperation partners.

In addition to the company headquarters in Dreieich (near Frankfurt, Germany), the Biotest Group includes companies for the distribution of products in Austria, Switzerland and Hungary as well as companies for plasma collection in Germany, Hungary and the Czech Republic.

2. Our guiding principles for human rights, health and safety, the environment, governance and dealing with suppliers

Protecting human rights is not only a central element of our corporate responsibility - our business purpose is to enable seriously ill people to survive and to help the chronically ill to achieve a better quality of life. We base our commitment to respecting human rights on the United Nations Universal Declaration of Human Rights (UDHR) of 1948 and the International Labor Organization (ILO) Declaration on Fundamental Principles and Rights at Work. We are committed to internationally recognized human rights and respect them in our business activities and along our value chains. This includes, in particular, the prohibition of child and forced labor, the prohibition of all forms of slavery, human trafficking and discrimination, and support for freedom of association.

We are unreservedly committed to upholding health and safety at work, the payment of appropriate wages, the prohibition of forced evictions and the inappropriate use of security forces, as well as the prohibition of environmental pollution if this entails the risk of human rights being disregarded or restricted. Among the environment-related international conventions, we are committed to the Minamata Convention, the Stockholm Convention on Persistent Organic Pollutants (POPs Convention) and the Basel Convention. We are also guided by the United Nations Global Compact, the Universal Declaration of Human Rights and the United Nations Guiding Principles on Business and Human Rights.

This declaration illustrates our fundamental commitment to respecting human rights, which is also reflected in other company guidelines. These include our Supplier Code of Conduct, the Biotest Code of Conduct and our Group-wide ESG efforts on the environment, sustainability and governance, as well as our voluntary commitment to sustainability and human rights. We also safeguard donors through a monitoring system. Haemovigilance is a systematic monitoring system primarily to ensure donor welfare, but also to continuously monitor and improve the actual donation process. Top priority is given to preventive protective measures for the donor; the aim for the donation process is the early detection of new risks and quality defects in plasma collection.

The principles set out here apply to our own business activities and all employees of the Biotest companies. In addition, we expect our suppliers and all other relevant business partners to undertake to comply with the principles set out here and to implement appropriate processes to respect human rights and environmental protection. This also includes providing information on request on how the aforementioned principles are complied with.

3. Implementation in the company

In order to comply with our due diligence obligations in accordance with the German Supply Chain Due Diligence Act (LkSG), we have implemented detailed processes to identify and analyze human rights and environmental risks and reduce their potential impact. Accordingly, we carry out risk analyses on an annual and ad hoc basis and pay particular attention to those risks that can occur in pharmaceutical value chains and especially in plasma collection. Where necessary, we always adapt this policy statement to current circumstances. We incorporate the results of our risk analyses into our business processes, in particular into our supplier management system.

The risk analysis carried out in 2023 showed that there could be potential risks in our supply chains when procuring plasma, construction services and, where applicable, workwear. We also monitor the plasma collection process and the treatment of donors in our value chain very closely. We counter these with the following general and specific preventive measures:

(a) Our new suppliers in critical industries and countries are screened for occupational safety, human rights and environmental criteria, among others. We repeat the risk assessment of existing suppliers at regular intervals. If human rights or environmental risks are identified, these are to be addressed with the suppliers as part of an established risk monitoring and risk elimination process and the implementation of effective remedial measures is to be pursued.

b) We endeavor to contractually obligate our suppliers to comply with our Supplier Code of Conduct. In business relationships with suppliers with a higher risk profile, we seek contractual audit rights. If we become aware of relevant violations by a supplier, we request that the supplier rectify the violation and, if necessary, terminate the respective business relationship as a last resort. In this way, we endeavor to ensure that upstream suppliers also comply with our principles.

c) We plan to conduct training in the relevant business areas. We endeavor to oblige our suppliers to inform their employees about compliance with the Supplier Code of Conduct in the relevant business areas and to train them accordingly.

d) The health and safety of our employees is our top priority. By implementing uniformly high standards at all our sites, we are continuously working to create a safe and healthy working environment. Our employees must take part in regular training courses to promote safety-conscious behavior.

e) As a company in the pharmaceutical industry, we are subject to strict product safety regulations. Compliance with the legal and internal requirements for Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Distribution Practice (GDP) and product safety are key issues for us. Biotest has had effective processes in place for decades to ensure the quality and safety of our products for patients (e.g. pharmacovigilance).

f) If our business activities cause or contribute to actual human rights violations, we are committed to implementing effective remedial measures. Biotest enables its employees and third parties to report grievances in our company and our suppliers via a whistleblowing process. The Human Rights Officer is

responsible for processing the reports. Violations within our supply chain can also be reported here. The complaints procedure is publicly and anonymously accessible via our website. We are working on further developing our grievance mechanisms and improving accessibility for internal and external stakeholders.

g) The Management Board of Biotest AG is responsible for the implementation of this policy statement.

4. Documentation / human rights officer

We document our efforts to effectively implement our due diligence obligations on an ongoing basis. In addition, we will publish an annual report on the fulfillment of our due diligence obligations. This will be published on our website for the first time in April 2025, no later than four months after the end of our financial year, and will be available free of charge for a period of seven years.

The office responsible for establishing and monitoring the human rights obligations set out here is the Human Rights Officer of Biotest AG.

Dreieich, 01 January 2024

Management Board of Biotest AG

Peter Janssen

Chairman of the Board of Management



.....

Ainhoa Mendizabal Zubiaga

Chief Financial Officer



.....

Dr Jörg Schüttrumpf

Chief Scientific Officer



.....